Longeveron Inc. (LGVN)
Longeveron Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Miami, FL, US. The stock last traded at $0.75, up 8.45% on the session, giving a market capitalisation of $15.0M. On trailing twelve-month figures it carries a trailing P/E of -0.65, a net margin of -1844.5%. Its beta of -0.25 implies it has historically moved less than the broad market.
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
Longeveron Inc. is most often compared with the following Healthcare names: